259 related articles for article (PubMed ID: 30025343)
1. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
[TBL] [Abstract][Full Text] [Related]
3. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
6. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
[TBL] [Abstract][Full Text] [Related]
9. Novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives: Design, synthesis, antiproliferative activity and DNA/RNA binding study.
Lončar B; Perin N; Mioč M; Boček I; Grgić L; Kralj M; Tomić S; Stojković MR; Hranjec M
Eur J Med Chem; 2021 May; 217():113342. PubMed ID: 33751978
[TBL] [Abstract][Full Text] [Related]
10. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
Zhang L; Bu T; Bao X; Liang T; Ge Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2017 Aug; 27(15):3395-3398. PubMed ID: 28633896
[TBL] [Abstract][Full Text] [Related]
12. Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation.
El-Naggar M; Almahli H; Ibrahim HS; Eldehna WM; Abdel-Aziz HA
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914120
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.
Lukasik PM; Elabar S; Lam F; Shao H; Liu X; Abbas AY; Wang S
Eur J Med Chem; 2012 Nov; 57():311-22. PubMed ID: 23085105
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and docking study of pyridine and thieno[2,3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors.
Abdelaziz ME; El-Miligy MMM; Fahmy SM; Mahran MA; Hazzaa AA
Bioorg Chem; 2018 Oct; 80():674-692. PubMed ID: 30064079
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel pyridine-thiazolidinone derivatives as anticancer agents: Targeting human carbonic anhydrase IX.
Ansari MF; Idrees D; Hassan MI; Ahmad K; Avecilla F; Azam A
Eur J Med Chem; 2018 Jan; 144():544-556. PubMed ID: 29289880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
